1
|
Parzyck CT, Gupta NK, Wu Y, Anil V, Bhatt L, Bouliane M, Gong R, Gregory BZ, Luo A, Sutarto R, He F, Chuang YD, Zhou T, Herranz G, Kourkoutis LF, Singer A, Schlom DG, Hawthorn DG, Shen KM. Absence of 3a 0 charge density wave order in the infinite-layer nickelate NdNiO 2. Nat Mater 2024; 23:486-491. [PMID: 38278983 PMCID: PMC10990928 DOI: 10.1038/s41563-024-01797-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Accepted: 01/03/2024] [Indexed: 01/28/2024]
Abstract
A hallmark of many unconventional superconductors is the presence of many-body interactions that give rise to broken-symmetry states intertwined with superconductivity. Recent resonant soft X-ray scattering experiments report commensurate 3a0 charge density wave order in infinite-layer nickelates, which has important implications regarding the universal interplay between charge order and superconductivity in both cuprates and nickelates. Here we present X-ray scattering and spectroscopy measurements on a series of NdNiO2+x samples, which reveal that the signatures of charge density wave order are absent in fully reduced, single-phase NdNiO2. The 3a0 superlattice peak instead originates from a partially reduced impurity phase where excess apical oxygens form ordered rows with three-unit-cell periodicity. The absence of any observable charge density wave order in NdNiO2 highlights a crucial difference between the phase diagrams of cuprate and nickelate superconductors.
Collapse
Grants
- DE-SC0019414 U.S. Department of Energy (DOE)
- DE-AC02-05CH11231 U.S. Department of Energy (DOE)
- DE-AC02-06CH11357 U.S. Department of Energy (DOE)
- FA9550-21-1-0168 United States Department of Defense | United States Air Force | AFMC | Air Force Office of Scientific Research (AF Office of Scientific Research)
- DMR-2104427 National Science Foundation (NSF)
- NNCI-2025233 National Science Foundation (NSF)
- GBMF3850 Gordon and Betty Moore Foundation (Gordon E. and Betty I. Moore Foundation)
- GBMF9073 Gordon and Betty Moore Foundation (Gordon E. and Betty I. Moore Foundation)
- Part of the research described in this paper was performed at the Canadian Light Source, a national research facility of the University of Saskatchewan, which is supported by the Canada Foundation for Innovation (CFI), the Natural Sciences and Engineering Research Council (NSERC), the National Research Council (NRC), the Canadian Institutes of Health Research (CIHR), the Government of Saskatchewan, and the University of Saskatchewan.
- The microscopy work at Cornell was supported by the NSF PARADIM, with additional support from Cornell University, the Weill Institute, the Kavli Institute at Cornell, and the Packard Foundation.
- G.H. acknowledges support from Severo Ochoa FUNFUTURE (No. CEX2019-000917-S) of the Spanish Ministry of Science and Innovation and by the Generalitat de Catalunya (2021 SGR 00445).
Collapse
Affiliation(s)
- C T Parzyck
- Laboratory of Atomic and Solid State Physics, Department of Physics, Cornell University, Ithaca, NY, USA
| | - N K Gupta
- Department of Physics and Astronomy, University of Waterloo, Waterloo, Ontario, Canada
| | - Y Wu
- Laboratory of Atomic and Solid State Physics, Department of Physics, Cornell University, Ithaca, NY, USA
| | - V Anil
- Laboratory of Atomic and Solid State Physics, Department of Physics, Cornell University, Ithaca, NY, USA
| | - L Bhatt
- School of Applied and Engineering Physics, Cornell University, Ithaca, NY, USA
| | - M Bouliane
- Department of Physics and Astronomy, University of Waterloo, Waterloo, Ontario, Canada
| | - R Gong
- Department of Physics and Astronomy, University of Waterloo, Waterloo, Ontario, Canada
| | - B Z Gregory
- Laboratory of Atomic and Solid State Physics, Department of Physics, Cornell University, Ithaca, NY, USA
- Department of Materials Science and Engineering, Cornell University, Ithaca, NY, USA
| | - A Luo
- Department of Materials Science and Engineering, Cornell University, Ithaca, NY, USA
| | - R Sutarto
- Canadian Light Source, Saskatoon, Saskatchewan, Canada
| | - F He
- Canadian Light Source, Saskatoon, Saskatchewan, Canada
| | - Y-D Chuang
- Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - T Zhou
- Center for Nanoscale Materials, Argonne National Laboratory, Lemont, IL, USA
| | - G Herranz
- Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Bellaterra, Spain
| | - L F Kourkoutis
- School of Applied and Engineering Physics, Cornell University, Ithaca, NY, USA
- Kavli Institute at Cornell for Nanoscale Science, Cornell University, Ithaca, NY, USA
| | - A Singer
- Department of Materials Science and Engineering, Cornell University, Ithaca, NY, USA
| | - D G Schlom
- Department of Materials Science and Engineering, Cornell University, Ithaca, NY, USA
- Kavli Institute at Cornell for Nanoscale Science, Cornell University, Ithaca, NY, USA
- Leibniz-Institut für Kristallzüchtung, Berlin, Germany
| | - D G Hawthorn
- Department of Physics and Astronomy, University of Waterloo, Waterloo, Ontario, Canada
| | - K M Shen
- Laboratory of Atomic and Solid State Physics, Department of Physics, Cornell University, Ithaca, NY, USA.
- Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Bellaterra, Spain.
- Kavli Institute at Cornell for Nanoscale Science, Cornell University, Ithaca, NY, USA.
| |
Collapse
|
2
|
Parzyck CT, Gupta NK, Wu Y, Anil V, Bhatt L, Bouliane M, Gong R, Gregory BZ, Luo A, Sutarto R, He F, Chuang YD, Zhou T, Herranz G, Kourkoutis LF, Singer A, Schlom DG, Hawthorn DG, Shen KM. Publisher Correction: Absence of 3a 0 charge density wave order in the infinite-layer nickelate NdNiO 2. Nat Mater 2024; 23:440. [PMID: 38347120 PMCID: PMC10917676 DOI: 10.1038/s41563-024-01832-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/15/2024]
Affiliation(s)
- C T Parzyck
- Laboratory of Atomic and Solid State Physics, Department of Physics, Cornell University, Ithaca, NY, USA
| | - N K Gupta
- Department of Physics and Astronomy, University of Waterloo, Waterloo, Ontario, Canada
| | - Y Wu
- Laboratory of Atomic and Solid State Physics, Department of Physics, Cornell University, Ithaca, NY, USA
| | - V Anil
- Laboratory of Atomic and Solid State Physics, Department of Physics, Cornell University, Ithaca, NY, USA
| | - L Bhatt
- School of Applied and Engineering Physics, Cornell University, Ithaca, NY, USA
| | - M Bouliane
- Department of Physics and Astronomy, University of Waterloo, Waterloo, Ontario, Canada
| | - R Gong
- Department of Physics and Astronomy, University of Waterloo, Waterloo, Ontario, Canada
| | - B Z Gregory
- Laboratory of Atomic and Solid State Physics, Department of Physics, Cornell University, Ithaca, NY, USA
- Department of Materials Science and Engineering, Cornell University, Ithaca, NY, USA
| | - A Luo
- Department of Materials Science and Engineering, Cornell University, Ithaca, NY, USA
| | - R Sutarto
- Canadian Light Source, Saskatoon, Saskatchewan, Canada
| | - F He
- Canadian Light Source, Saskatoon, Saskatchewan, Canada
| | - Y-D Chuang
- Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - T Zhou
- Center for Nanoscale Materials, Argonne National Laboratory, Lemont, IL, USA
| | - G Herranz
- Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Bellaterra, Spain
| | - L F Kourkoutis
- School of Applied and Engineering Physics, Cornell University, Ithaca, NY, USA
- Kavli Institute at Cornell for Nanoscale Science, Cornell University, Ithaca, NY, USA
| | - A Singer
- Department of Materials Science and Engineering, Cornell University, Ithaca, NY, USA
| | - D G Schlom
- Department of Materials Science and Engineering, Cornell University, Ithaca, NY, USA
- Kavli Institute at Cornell for Nanoscale Science, Cornell University, Ithaca, NY, USA
- Leibniz-Institut für Kristallzüchtung, Berlin, Germany
| | - D G Hawthorn
- Department of Physics and Astronomy, University of Waterloo, Waterloo, Ontario, Canada
| | - K M Shen
- Laboratory of Atomic and Solid State Physics, Department of Physics, Cornell University, Ithaca, NY, USA.
- Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Bellaterra, Spain.
- Kavli Institute at Cornell for Nanoscale Science, Cornell University, Ithaca, NY, USA.
| |
Collapse
|
3
|
Bhatt L, Gupta R. Potent anticolorectal cancer activity of 5-fluorouracil and laccaic acid combination via modulation of epigenetic regulation. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
4
|
Margaroli C, Bradley B, Bhatt L, Ahuja S, Springman E, Tirouvanziam R, Feldman R. 1034 Leukotriene B4 pathway and tissue damage markers are expressed by granulocytes in lesional skin in bullous pemphigoid. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.1110] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Lavin V, Mehta S, Sumra P, Wang X, Bhatt L, Jackson A, Sheikh H. Experience of Definitive Chemoradiation for Oesophageal Cancer Within a Large Regional Cancer Treatment Centre: Improving Outcomes and Tolerability. Clin Oncol (R Coll Radiol) 2018; 30:650-657. [DOI: 10.1016/j.clon.2018.07.022] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2018] [Revised: 06/12/2018] [Accepted: 07/04/2018] [Indexed: 12/01/2022]
|
6
|
Marti FM, McGurk A, Alam N, Bhatt L, Braun M, Hubner R, Mansoor W, McBain C, McNamara M, Mullamitha S, Saunders M, Sheikh H, Thistlethwaite F, Valle J, Wilson G, Hasan J. 30-day mortality associated with systemic anti-cancer therapy (SACT) in gastrointestinal malignancies: The Christie experience. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
7
|
Bhatt L, Roinestad K, Van T, Springman E. Recent advances in clinical development of leukotriene B4 pathway drugs. Semin Immunol 2017; 33:65-73. [DOI: 10.1016/j.smim.2017.08.007] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Revised: 05/04/2017] [Accepted: 08/08/2017] [Indexed: 12/23/2022]
|
8
|
|
9
|
Elborn JS, Bhatt L, Grosswald R, Ahuja S, Springman EB. Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction. Clin Transl Sci 2016; 10:20-27. [PMID: 27792868 PMCID: PMC5351008 DOI: 10.1111/cts.12426] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Accepted: 09/22/2016] [Indexed: 01/07/2023] Open
Abstract
Acebilustat is a new once-daily oral antiinflammatory drug in development for treatment of cystic fibrosis (CF) and other diseases. It is an inhibitor of leukotriene A4 hydrolase; therefore, production of leukotriene B4 (LTB4) in biological fluids provides a direct measure of the pharmacodynamic (PD) response to acebilustat treatment. Here we compare the pharmacokinetics (PK) and PD between CF patients and healthy volunteers, and investigate the food effect and CYP3A4 induction in healthy volunteers. No significant differences between study populations were observed for peak plasma level (Cmax ) or exposure (AUC). In healthy volunteers, a shift in time to Cmax (Tmax ) was observed after a high-fat meal, but there was no change in AUC. LTB4 production was reduced in the blood of both populations and in sputum from CF patients. Acebilustat did not induce CYP3A4. These results support continued clinical study of once-daily oral acebilustat in CF at doses of 50 and 100 mg.
Collapse
Affiliation(s)
- J S Elborn
- Queen's University Belfast, Belfast, United Kingdom of Great Britain and Northern Ireland
| | - L Bhatt
- Celtaxsys, Inc, Atlanta, Georgia, United States
| | - R Grosswald
- Celtaxsys, Inc, Atlanta, Georgia, United States
| | - S Ahuja
- Celtaxsys, Inc, Atlanta, Georgia, United States
| | | |
Collapse
|
10
|
Lavin V, Sheikh H, Bhatt L. Preoperative Chemoradiotherapy for Oesophageal Cancer: A Tolerable and Effective Strategy. Clin Oncol (R Coll Radiol) 2016; 28:668. [PMID: 27339404 DOI: 10.1016/j.clon.2016.06.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2016] [Accepted: 06/08/2016] [Indexed: 10/21/2022]
Affiliation(s)
- V Lavin
- Christie Hospital NHS Foundation Trust, Manchester, UK
| | - H Sheikh
- Christie Hospital NHS Foundation Trust, Manchester, UK
| | - L Bhatt
- Christie Hospital NHS Foundation Trust, Manchester, UK
| |
Collapse
|
11
|
Sumra P, Arthur C, Jackson A, Bhatt L, Sheikh H. 2270 Patterns of relapse following definitive chemoradiotherapy for oesophageal carcinoma - is there a case for elective nodal irradiation? Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31186-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
12
|
Springman E, Bhatt L, Grosswald R, Philpot E. 127 Pharmacokinetic and pharmacodynamic profile of CTX-4430 in two phase 1 studies. J Cyst Fibros 2015. [DOI: 10.1016/s1569-1993(15)30304-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Mehta S, Mcpartlin A, NikMutasim A, Arthur C, Bhatt L, Jackson A, Sheikh H. EP-1207: Relapse patterns and outcomes following radiotherapy alone for oesophageal cancer: a single UK centre experience. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41199-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
14
|
Bhatt L, Tirmazy S, Sothi S. Intraluminal high-dose-rate brachytherapy for palliation of dysphagia in cancer of the esophagus: initial experience at a single UK center. Dis Esophagus 2013; 26:57-60. [PMID: 22404484 DOI: 10.1111/j.1442-2050.2012.01333.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Esophageal cancer tends to present with advanced disease, and the majority of patients are suitable only for palliative treatment at diagnosis. Dysphagia is the most common presenting symptom and significantly undermines quality of life. High-dose-rate intraluminal brachytherapy (ILBT) has been an option for the palliation of dysphagia for many years and has been used at our center since 2006. Experience was presented in terms of improvement of dysphagia and survival. Patients were identified from the local radiotherapy database. Original treatment sheets and clinical notes were reviewed retrospectively to obtain treatment details, pretreatment and post-treatment dysphagia scores, and survival information. Between January 2006 and January 2010, 21 patients of median age 77 years with a mean pretreatment dysphagia score of 2.5 underwent ILBT for esophageal cancer. All received 12 Gy in a single fraction. Thirteen (62%) had adenocarcinoma and eight (38%) squamous cell carcinoma. Four (19%) tumors were in the mid-esophagus and 17 (81%) in the lower esophagus. Eight had extension of tumor into the gastroesophageal junction. Seven patients (33%) received chemotherapy as first-line treatment prior to brachytherapy. Nineteen patients had clear documentation of dysphagia scores both pretreatment and post-treatment, and the improvement overall was significant (P= 0.04). Ten patients (53%) had an improvement in dysphagia score. Five of these (50%) went on to require further endoscopic intervention due to disease progression. Median duration of response was 4 months. Of the nonresponders, six (67%) went on to require further endoscopic intervention. No patients experienced documented toxicity aside from a short-lived acute esophagitis. Median survival from date of diagnosis was 12 months and from treatment date was 5 months (1-32 months). In our series of elderly patients with significant dysphagia, ILBT was a well-tolerated and effective treatment. It should be considered as a palliative option in esophageal cancer.
Collapse
Affiliation(s)
- L Bhatt
- Arden Cancer Centre, University Hospital, Coventry, UK.
| | | | | |
Collapse
|
15
|
Bhatt L, King M, Pirrie S, Anwar MS, El-Modir A, Fernando IN. Survival and toxicity following chemoradiation for carcinoma of the cervix: Impact of multiple phase treatment and shielding. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Wong D, Lupton S, Bhatt L, Gross L, Tanière P, Peake D, Spooner D, Geh J. Use of Imatinib Mesylate in Gastrointestinal Stromal Tumours: Pan-Birmingham Cancer Network Experience. Clin Oncol (R Coll Radiol) 2008; 20:517-22. [DOI: 10.1016/j.clon.2008.04.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2007] [Revised: 03/31/2008] [Accepted: 04/01/2008] [Indexed: 10/22/2022]
|
17
|
Bourne TH, Campbell S, Reynolds K, Hampson J, Bhatt L, Crayford TJ, Whitehead MI, Collins WP. The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer. Gynecol Oncol 1994; 52:379-85. [PMID: 8157195 DOI: 10.1006/gyno.1994.1065] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
We have assessed the potential role of a test based upon the measurement of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer. A sample of peripheral blood was taken from 1502 self-referred, asymptomatic women whose pedigree showed that at least one close relative had developed the disease. All women in the study underwent one screening by transvaginal ultrasonography (consisting of one or more scans) to detect any persistent lesion and a change in ovarian volume. Women with a positive result were referred for surgery. The concentration of serum CA 125 was measured in all samples at the end of the study. Seven ovarian cancers (4 invasive and 3 of borderline malignancy; 5 FIGO stage Ia, 1 stage IIa, 1 stage III) and 55 benign lesions were detected. We calculated the effect that a prescreening test (based on different threshold values for serum CA 125) would have had on the number of women entering the ultrasound-based screening program, and on the detection rate and false-positive rate of the overall procedure. There was a direct relationship between the number of women referred for ultrasound screening and the detection rate. The use of a threshold value for serum CA 125 > or = 20 U/ml would have meant that 380 women (25.3%) were referred for ultrasonography and 5 out of 7 cancers (71%) would have been detected with a false-positive rate of 1.1%. The odds of a woman with a positive screening result having cancer at surgery would have been about 1:3 (which would improve to about 1:1 if observational indices of color Doppler imaging and a morphological score had been used throughout). We concluded that a prescreening immunochemical test based on the measurement of serum CA 125 (with a threshold value of > or = 20 U/ml) would increase the prior odds for familial ovarian cancer by 2.8, but would lower the overall detection rate by 29% at the prevalence screening.
Collapse
Affiliation(s)
- T H Bourne
- Academic Department of Obstetrics and Gynaecology, King's College School of Medicine and Dentistry, Denmark Hill, London, United Kingdom
| | | | | | | | | | | | | | | |
Collapse
|